Piper Sandler Reiterates Overweight on Biogen, Raises Price Target to $305
Benzinga Newsdesk 22 hours ago
Analyst RatingsNewsReiterationPrice Target
Piper Sandler analyst David Amsellem reiterates Biogen (NASDAQ:BIIB) with a Overweight and raises the price target from $245 to $305.
Piper Sandler analyst David Amsellem reiterates Biogen (NASDAQ:BIIB) with a Overweight and raises the price target from $245 to $305.